Evvy Launches At-Home UTI Test Built for Fast, Accurate, and Targeted Care

Audio By Carbonatix

NEW YORK--(BUSINESS WIRE)--Dec 9, 2025--

Evvy, the precision women’s health company, today announced the launch of the Evvy UTI+ Test, a comprehensive at-home urine test that uses PCR technology to detect 12 key uropathogens and 7 antibiotic resistance markers — delivering results in just 1 business day. If eligible, patients can also receive same-day, targeted prescription care based on their unique results – eliminating the trial-and-error cycle that has defined UTI care for decades.

UTIs are the most common infection in U.S. women, and yet the current standard of care can be slow, outdated, and inaccurate. Standard urine cultures can miss up to60–70%of pathogens, and results often take days to return. As a result, nearly1 in 2women receive an antibiotic that may not effectively address their infection, leading to prolonged symptoms, repeat appointments, and unnecessary antibiotic exposure. Evvy’s UTI+ Test directly addresses these failures with fast, accurate results and precision Rx options.

“At Evvy, we believe women deserve better than guesswork,” said Dr. Kate McLean, OBGYN and Chief Medical Officer at Evvy. “We designed the UTI+ Test to solve a big failure of current UTI care: incomplete detection. By using PCR to identify 12 key pathogens, we can treat UTIs with accuracy and precision. The result is simple but profound – patients finally get better without the trial-and-error approach that has plagued UTI care for generations.”

For the 1 in 4 women who experience recurring UTIs, Evvy can offer additional insight through their vaginal microbiome test. Emerging research shows that the vaginal microbiome can play a key role in urinary health by acting as a reservoir for UTI-causing bacteria — and Evvy’s own dataset reflects this: 47% of Evvy users who reported a recent UTI had UTI-related bacteria detected by Evvy in their vaginal microbiome.

The launch of the UTI+ Test marks a major expansion of Evvy’s precision women’s health ecosystem, which now integrates testing for the vaginal microbiome, UTIs, and STIs with personalized prescription care and 1:1 coaching to bring women and people with vaginas the care they deserve.

The UTI+ Test is available now in the U.S. (except AK, HI, NY) at evvy.com for $248, or $218 with a subscription.

About Evvy:

Founded in 2021, Evvy is closing the gender health gap by leveraging overlooked female biomarkers, starting with the vaginal microbiome. The company offers the world’s first Vaginal Microbiome Test powered by metagenomic sequencing, analyzing over 700 microbes with a single, at-home swab — including those related to bacterial vaginosis, yeast infections, fertility outcomes, and more. Evvy’s care platform also includes precision treatment pathways from licensed clinicians and 1:1 health coaching. Through their test and care platform, Evvy has built the world’s largest dataset on the vaginal microbiome, and they are leveraging this novel data to improve outcomes across women’s health.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251209514522/en/

CONTACT: Media Contact:

Jess Bryant

SolComms

[email protected]

KEYWORD: NEW YORK UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: GENERAL HEALTH WOMEN CONSUMER HEALTH PHARMACEUTICAL

SOURCE: Evvy

Copyright Business Wire 2025.

PUB: 12/09/2025 09:00 AM/DISC: 12/09/2025 09:02 AM

http://www.businesswire.com/news/home/20251209514522/en